Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CPRXNASDAQ:SMMTNASDAQ:SNDXNASDAQ:XNCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCPRXCatalyst Pharmaceuticals$24.49+1.6%$23.53$14.75▼$26.16$2.99B0.71.11 million shs772,723 shsSMMTSummit Therapeutics$25.85+0.3%$23.00$2.10▼$36.91$19.20B-0.943.88 million shs1.76 million shsSNDXSyndax Pharmaceuticals$9.85-8.9%$11.83$8.58▼$25.07$847.56M0.821.77 million shs3.90 million shsXNCRXencor$7.57-1.6%$9.67$7.16▼$27.24$538.76M0.99653,695 shs841,099 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCPRXCatalyst Pharmaceuticals+1.58%+0.49%+5.93%+13.24%+51.73%SMMTSummit Therapeutics+0.31%+8.29%-22.31%+16.86%+488.84%SNDXSyndax Pharmaceuticals-8.88%+8.84%-24.32%-39.87%-52.55%XNCRXencor-1.56%-6.08%-30.47%-51.91%-69.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCPRXCatalyst Pharmaceuticals4.6357 of 5 stars3.61.00.03.93.73.32.5SMMTSummit Therapeutics3.0268 of 5 stars4.52.00.00.03.71.70.0SNDXSyndax Pharmaceuticals3.8085 of 5 stars4.51.00.04.43.00.00.0XNCRXencor3.7603 of 5 stars3.41.00.03.92.90.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCPRXCatalyst Pharmaceuticals 3.13Buy$32.2931.83% UpsideSMMTSummit Therapeutics 3.09Buy$37.4044.68% UpsideSNDXSyndax Pharmaceuticals 2.91Moderate Buy$35.91264.56% UpsideXNCRXencor 2.89Moderate Buy$29.50289.70% UpsideCurrent Analyst Ratings BreakdownLatest SMMT, CPRX, XNCR, and SNDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025SMMTSummit TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025XNCRXencorBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$22.00 ➝ $6.005/6/2025SNDXSyndax PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.005/6/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.005/2/2025SMMTSummit TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $41.004/30/2025XNCRXencorWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$31.004/28/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.004/28/2025SMMTSummit TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$40.00 ➝ $40.004/25/2025SMMTSummit TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$31.00 ➝ $44.004/23/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight4/21/2025XNCRXencorWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCPRXCatalyst Pharmaceuticals$534.65M5.59$2.28 per share10.72$3.30 per share7.42SMMTSummit Therapeutics$700K27,425.59N/AN/A$0.11 per share235.00SNDXSyndax Pharmaceuticals$43.72M19.39N/AN/A$6.53 per share1.51XNCRXencor$127.23M4.23N/AN/A$10.99 per share0.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCPRXCatalyst Pharmaceuticals$71.41M$1.5720.7511.503.3131.01%40.79%34.87%8/6/2025 (Estimated)SMMTSummit Therapeutics-$614.93M-$0.34N/AN/AN/AN/A-85.42%-52.66%8/5/2025 (Estimated)SNDXSyndax Pharmaceuticals-$209.36M-$3.86N/AN/AN/AN/A-64.34%-57.72%8/7/2025 (Estimated)XNCRXencor-$126.09M-$3.06N/AN/AN/A-232.77%-30.92%-21.74%8/4/2025 (Estimated)Latest SMMT, CPRX, XNCR, and SNDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025XNCRXencor-$0.60-$0.66-$0.06-$0.66$23.44 million$32.73 million5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 million5/1/2025Q1 2025SMMTSummit Therapeutics-$0.10-$0.09+$0.01-$0.09N/AN/A3/3/2025Q4 2024SNDXSyndax Pharmaceuticals-$0.31-$1.10-$0.79-$1.10$86.32 million$7.68 million2/27/2025Q4 2024XNCRXencor-$0.81-$0.62+$0.19-$0.62$17.14 million$52.79 million2/24/2025Q4 2024SMMTSummit Therapeutics-$0.08-$0.08N/A-$0.08N/A$0.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCPRXCatalyst PharmaceuticalsN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/AXNCRXencorN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCPRXCatalyst PharmaceuticalsN/A5.114.92SMMTSummit TherapeuticsN/A8.318.31SNDXSyndax PharmaceuticalsN/A6.996.99XNCRXencor0.016.236.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCPRXCatalyst Pharmaceuticals79.22%SMMTSummit Therapeutics4.61%SNDXSyndax PharmaceuticalsN/AXNCRXencorN/AInsider OwnershipCompanyInsider OwnershipCPRXCatalyst Pharmaceuticals10.40%SMMTSummit Therapeutics84.90%SNDXSyndax Pharmaceuticals4.10%XNCRXencor4.76%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCPRXCatalyst Pharmaceuticals80121.98 million106.15 millionOptionableSMMTSummit Therapeutics110742.67 million86.28 millionOptionableSNDXSyndax Pharmaceuticals11086.05 million81.86 millionOptionableXNCRXencor28071.17 million66.32 millionOptionableSMMT, CPRX, XNCR, and SNDX HeadlinesRecent News About These CompaniesXencor (NASDAQ:XNCR) vs. Dermata Therapeutics (NASDAQ:DRMA) Financial ComparisonMay 19, 2025 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Shares Acquired by RTW Investments LPMay 18, 2025 | marketbeat.comPoint72 Asset Management L.P. Sells 943,148 Shares of Xencor, Inc. (NASDAQ:XNCR)May 18, 2025 | marketbeat.comNorthern Trust Corp Increases Holdings in Xencor, Inc. (NASDAQ:XNCR)May 17, 2025 | marketbeat.comBrokerages Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $29.50May 17, 2025 | americanbankingnews.comXencor, Inc. (NASDAQ:XNCR) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 16, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Raises Stock Position in Xencor, Inc. (NASDAQ:XNCR)May 15, 2025 | marketbeat.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA)May 13, 2025 | theglobeandmail.comLeerink Partnrs Has Bearish Forecast for Xencor Q2 EarningsMay 13, 2025 | marketbeat.comWedbush Comments on Xencor's Q2 Earnings (NASDAQ:XNCR)May 13, 2025 | marketbeat.comResearch Analysts Set Expectations for Xencor Q2 EarningsMay 13, 2025 | marketbeat.comDeep Track Capital LP Has $11.49 Million Stake in Xencor, Inc. (NASDAQ:XNCR)May 9, 2025 | marketbeat.comBraidwell LP Buys 149,083 Shares of Xencor, Inc. (NASDAQ:XNCR)May 8, 2025 | marketbeat.comXencor Reports First Quarter 2025 Financial ResultsMay 7, 2025 | uk.finance.yahoo.comXencor (XNCR) Reports Q1 Loss, Tops Revenue EstimatesMay 7, 2025 | zacks.comXencor (NASDAQ:XNCR) Trading Down 6.1% - Should You Sell?May 7, 2025 | marketbeat.comXencor, Inc. (NASDAQ:XNCR) EVP Nancy Valente Sells 4,616 SharesMay 7, 2025 | insidertrades.comDimensional Fund Advisors LP Grows Position in Xencor, Inc. (NASDAQ:XNCR)May 7, 2025 | marketbeat.comBVF Inc. IL Acquires 1,438,760 Shares of Xencor, Inc. (NASDAQ:XNCR)May 6, 2025 | marketbeat.comXencor (XNCR) Expected to Announce Earnings on ThursdayMay 3, 2025 | marketbeat.comRaymond James Financial Inc. Invests $2.33 Million in Xencor, Inc. (NASDAQ:XNCR)May 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSMMT, CPRX, XNCR, and SNDX Company DescriptionsCatalyst Pharmaceuticals NASDAQ:CPRX$24.49 +0.38 (+1.58%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$24.34 -0.15 (-0.59%) As of 05/23/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.Summit Therapeutics NASDAQ:SMMT$25.85 +0.08 (+0.31%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$25.72 -0.14 (-0.52%) As of 05/23/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.Syndax Pharmaceuticals NASDAQ:SNDX$9.85 -0.96 (-8.88%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$10.22 +0.37 (+3.76%) As of 05/23/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Xencor NASDAQ:XNCR$7.57 -0.12 (-1.56%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$7.38 -0.19 (-2.50%) As of 05/23/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
